Iovance Biotherapeutics Inc (NAS:IOVA)
$ 8.01 0.04 (0.5%) Market Cap: 2.24 Bil Enterprise Value: 1.96 Bil PE Ratio: 0 PB Ratio: 3.30 GF Score: 40/100

Iovance Biotherapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days Transcript

Feb 11, 2021 / 05:00PM GMT
Release Date Price: $47.75 (-1.65%)
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD

Okay. Hello. I'm Michael Schmidt, Senior Biotech Analyst with Guggenheim Securities, and it's my pleasure to welcome Maria Fardis, who is the CEO of Iovance Therapeutics (sic) [Iovance Biotherapeutics]. Maria, welcome, and thanks for joining us.

Maria Fardis
Iovance Biotherapeutics, Inc. - CEO, President & Director

Thank you so much for having us.

Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD

Great. So before we go through Q&A, would you like to give a quick overview for those who are less familiar with the company?

Maria Fardis
Iovance Biotherapeutics, Inc. - CEO, President & Director

Yes, absolutely. So Iovance Biotherapeutics is a company that is developing cell therapy -- autologous cell therapy for patients with solid tumors. We are developing tumor-infiltrating lymphocytes or TIL technology for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot